The test evaluates the specimen, such as serum, for acetylcholine receptor (AChR) modulating antibody using a method such as immunofluorescence assay. The level of this noninfectious agent antibody may indicate that the patient has myasthenia gravis (MG), an autoimmune disorder that disrupts the interface of nerve and muscle, resulting in muscle weakness.
For clinical responsibility, terminology, tips and additional info
start codify free trial.